{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:13:09Z","timestamp":1777666389354,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[1991,9,1]],"date-time":"1991-09-01T00:00:00Z","timestamp":683683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hum Exp Toxicol"],"published-print":{"date-parts":[[1991,9]]},"abstract":"<jats:p>1 The study objective was to determine the hyperphosphataemic and hypocalcaemic effect of hypertonic phosphate enema. The study was conducted in a department of Internal Medicine at a University Medical Center.<\/jats:p>\n                  <jats:p>\n                    2 Fourteen patients were studied. Patients' mean age (\u00b1 s.d.) was 78.5 \u00b1 9 years. The creatinine clearance was 48.2 \u00b1 17.4 ml min\n                    <jats:sup>-1<\/jats:sup>\n                    (mean \u00b1 s.d.).\n                  <\/jats:p>\n                  <jats:p>\n                    3 500 ml (approx. 7 ml kg\n                    <jats:sup>-1<\/jats:sup>\n                    ) of Fleet enema (FE - Na\n                    <jats:sub>2<\/jats:sub>\n                    HPO\n                    <jats:sub>4<\/jats:sub>\n                    .7H\n                    <jats:sub>2<\/jats:sub>\n                    O 224 mmol l\n                    <jats:sup>-1<\/jats:sup>\n                    and NaH\n                    <jats:sub>2<\/jats:sub>\n                    PO\n                    <jats:sub>4<\/jats:sub>\n                    .H\n                    <jats:sub>2<\/jats:sub>\n                    O 1160 mmol l\n                    <jats:sup>-1<\/jats:sup>\n                    ) were administered to each patient. Blood was drawn before FE administration and \u00bd, 1, 3, 5, 12 and 24 h thereafter. Serum was analysed for levels of inorganic phosphorus and for calcium.\n                  <\/jats:p>\n                  <jats:p>\n                    4 The serum inorganic phosphorus level rose from 1.01 \u00b1 0.3 mmol l\n                    <jats:sup>-1<\/jats:sup>\n                    to 1.4 \u00b1 0.5 mmol l\n                    <jats:sup>-1<\/jats:sup>\n                    ( P = 0.001) 1 h after FE was administered. Serum calcium decreased from 2.32 \u00b1 0.12 mmol l\n                    <jats:sup>-1<\/jats:sup>\n                    to 2.12 \u00b1 0.1 mmol l\n                    <jats:sup>-1<\/jats:sup>\n                    ( P &lt; 0.001) 12 h after FE was administered.\n                  <\/jats:p>\n                  <jats:p>5 We conclude that FE carries a potential risk for acutely ill elderly patients. To avoid untoward effects due to hyperphosphataemia and hypocalcaemia, the phosphate load must be adjusted to the patient's renal function, i.e. enema volume is to be lowered when phosphate concentration is high, so that if renal function is compromised the amount of phosphate absorbed does not exceed renal excretion capacity.<\/jats:p>","DOI":"10.1177\/096032719101000509","type":"journal-article","created":{"date-parts":[[2008,12,24]],"date-time":"2008-12-24T01:08:04Z","timestamp":1230080884000},"page":"351-355","source":"Crossref","is-referenced-by-count":17,"title":["Hyperphosphataemia and Hypocalcaemia Induced by Hypertonic Phosphate Enema - An Experimental Study and Review of the Literature"],"prefix":"10.1177","volume":"10","author":[{"given":"Itamar","family":"Grosskopf","sequence":"first","affiliation":[{"name":"Department of Internal Medicine 'C', Rokach Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eran","family":"Graff","sequence":"additional","affiliation":[{"name":"Biochemical Laboratory, Ichilov Hospital, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Charach","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 'C', Rokach Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Binyamin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 'C', Rokach Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Spinrad","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 'C', Rokach Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Blum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 'C', Rokach Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1991,9,1]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(77)80027-9"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1986.tb115928.x"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1974.02110230130023"},{"key":"atypb4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1542\/peds.53.1.105","volume":"127","author":"Oxnard SC","year":"1974","journal-title":"Pediatrics"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1177\/000992287501400717"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(77)80723-3"},{"key":"atypb7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1542\/peds.60.3.305","volume":"60","author":"Sotos JF","year":"1977","journal-title":"Pediatrics"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198312000-00020"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92605-4"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90064-6"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-198510000-00023"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1987.03390160076030"},{"key":"atypb13","first-page":"968","volume":"76","author":"Rao KJ","year":"1976","journal-title":"New York State Journal of Medicine"},{"key":"atypb14","first-page":"237","volume":"25","author":"Spinrad S.","year":"1989","journal-title":"Israel Journal of Medical Science"},{"key":"atypb15","unstructured":"Martindale, The Extra Pharmacopoeia , 29th edn, ed. EF Reynolds, pp. 1035. London: The Pharmaceutical Press, 1989."},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1177\/096032718600500109"},{"key":"atypb17","first-page":"302","volume":"124","author":"Coburn JW","year":"1969","journal-title":"Internal Medicine"},{"key":"atypb18","first-page":"980","volume":"46","author":"Atkins CE","year":"1985","journal-title":"American Journal of Veterinary Research"}],"container-title":["Human &amp; Experimental Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/096032719101000509","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/096032719101000509","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:42:41Z","timestamp":1777448561000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/096032719101000509"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1991,9]]}},"alternative-id":["10.1177\/096032719101000509"],"URL":"https:\/\/doi.org\/10.1177\/096032719101000509","relation":{},"ISSN":["0960-3271","1477-0903"],"issn-type":[{"value":"0960-3271","type":"print"},{"value":"1477-0903","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991,9]]}}}